The 18th Frost & Sullivan China Growth, Innovation and Leadership Summit and the 3rd New Investment Conference Life Sciences New Investment Summit Forum were held in Shanghai from August 28th to 29th, 2024. The forum brought together more than 40 industry leaders, biopharmaceutical companies, medical device companies, investment institutions and professional service providers. With the theme of "Responding to Changes and Opening New Horizons," all participants discussed new models of investment cooperation, aiming to build a closer, more efficient and win-win cooperation network, and jointly promote the vigorous development of the domestic and international life sciences industry.
At this forum, Dr. Li Haihan, Chief Technology Officer of Chuangjian Medical, introduced the development and application of recombinant collagen as a new type of medical material.
Dr. Li Haihan, Chief Technology Officer of Chuangjian Medical
The following are the key points from Dr. Li Haihang's speech:
A New Chapter in Synthetic Biology
Dr. Li Haihang first introduced the new progress in synthetic biology in the medical field. He mentioned that Chinese scientists have made a historic breakthrough in artificial synthesis of starch technology, which not only provides new ideas for starch industry manufacturing but also opens up new avenues for carbon dioxide utilization. This technology converts carbon dioxide into carbohydrates by mimicking the natural Calvin cycle, laying the foundation for future sustainable bio-manufacturing. Synthetic biology is playing a role in broader human societies.
Collagen medical applications
In introducing the field of collagen, Dr. Li Haihang first emphasized the wide application of recombinant collagen in the medical field. He first introduced the relevant distribution of different types of collagen in human tissues, pointing out that collagen is crucial for maintaining the tissue structure and function of the human body; he further shared scientific research results on the molecular structure and arrangement of collagen, as well as the key technological processes for the development and production of recombinant collagen. The analysis based on current research progress deepened people's understanding of the biological functions of collagen. At the same time, Dr. Li Haihang also pointed out that recombinant collagen can provide new possibilities for the development of novel medical materials and treatment methods.
Clinical Cases and Product Forms of Recombinant Collagen
Dr. Li Haihang demonstrated the significant effects of recombinant collagen products in treating complex wounds such as burns through clinical cases. He mentioned that the use of type III protein gel and XVII-type freeze-dried fibers can significantly promote the regeneration and repair of the skin basement membrane in burn patients' wounds. The development of these innovative products based on recombinant collagen reflects the tremendous potential of synthetic biology in solving clinical problems.
Future Outlook
Dr. Li Haihang is full of confidence in the future of synthetic biology and recombinant collagen. He believes that with continuous technological progress, research and application in these fields will bring more innovative solutions to healthcare. He predicts that synthetic biology will play an increasingly important role in the future medical field, especially in personalized medicine and regenerative medicine. Jiangsu Chuangjian Medical will also continue to conduct in-depth research and promote innovative practices in this area, driving the application of recombinant collagen and synthetic biology in a wider range of fields.
